Pharmstandard JSC
https://pharmstd.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharmstandard JSC
J&J Pledges $500m To Eliminate HIV and TB
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
J&J Says Bedaquiline TB Treatment Cost ‘Fair,’ $1/Day Price ‘Unrealistic’
Johnson & Johnson maintains its game-changing antibiotic bedaquiline for drug-resistant tuberculosis is priced "fairly" at $400 for a six-month course, and terms calls by public health advocates to cut the cost to $1 a day “not realistic.”
Deal Watch: Bayer/CRISPR Link-up Highlights Spate Of Deals At Year-End
Lilly is the latest established biopharma to license Halozyme's EXTENZE subcutaneous delivery technology. Mallinckrodt pays $175m up front to The Medicines Co. for a trio of topical hemostasis drugs.
Deals Shaping The Medical Industry, September 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Phs-Leksredstva JSC
- Pharmstandard-UfaVITA JSC
- PHS-Tomskhimpharm JSC
- LEKKO CJSC
- Biomed Mechnikov JSC
- Pharmstandard OJSC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice